Heritage Oak Wealth Advisors LLC Buys New Position in Cencora, Inc. (NYSE:COR)

Heritage Oak Wealth Advisors LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,244 shares of the company's stock, valued at approximately $731,000.

A number of other large investors also recently added to or reduced their stakes in COR. Fisher Asset Management LLC purchased a new position in shares of Cencora in the fourth quarter worth $244,000. Trust Co. of Vermont purchased a new stake in Cencora in the 4th quarter worth $62,000. Wahed Invest LLC bought a new position in shares of Cencora during the 4th quarter valued at about $567,000. Vanguard Group Inc. purchased a new position in shares of Cencora during the fourth quarter valued at about $4,212,508,000. Finally, Hennessy Advisors Inc. bought a new stake in shares of Cencora in the fourth quarter worth about $3,307,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Down 0.4 %

NYSE COR traded down $0.86 during trading on Tuesday, hitting $224.22. The stock had a trading volume of 1,338,934 shares, compared to its average volume of 1,412,257. Cencora, Inc. has a one year low of $178.21 and a one year high of $247.66. The stock has a 50 day simple moving average of $234.97 and a 200 day simple moving average of $232.60. The stock has a market capitalization of $44.72 billion, a price-to-earnings ratio of 24.63, a P/E/G ratio of 1.58 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.18 by $0.16. The company had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. Cencora's quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.92 EPS. Sell-side analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend was Friday, August 9th. Cencora's dividend payout ratio (DPR) is presently 22.32%.

Analysts Set New Price Targets

COR has been the topic of a number of research reports. StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Leerink Partners reaffirmed an "outperform" rating and set a $275.00 price target on shares of Cencora in a research note on Thursday, June 27th. Bank of America reissued a "neutral" rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Robert W. Baird decreased their target price on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating on the stock in a research report on Friday, September 6th. Finally, Wells Fargo & Company increased their price target on shares of Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $256.67.

Insider Activity

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm's stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the firm's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. Corporate insiders own 15.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.